Paul Weiss, Kirkland Steer $10.9B AbbVie, Apogee Deal
AbbVie said Monday it has agreed to buy Apogee Therapeutics, a company developing therapies for inflammatory and immunological diseases, at a total equity value of approximately $10.9 billion, with Paul Weiss Rifkind...To view the full article, register now.
Already a subscriber? Click here to view full article